AI is moving quickly from experimentation to practical adoption across life sciences. The opportunity is real, but so is the noise. Predictive AI, generative AI, agentic systems, AI co-scientists, foundation models, digital biomarkers and workflow automation are all competing for attention, investment and partnership dollars. For innovators and pharma R&D leaders, the key question is no longer whether AI will matter. It is which capabilities will become embedded in the way medicines are discovered and developed, and which will remain temporary hype.
Johnson & Johnson invites external innovators, investors, academic leaders and ecosystem partners to an afternoon discussion in Basel on what will make AI stick in pharma R&D. The program will examine where AI is already showing durable value, where expectations may be running ahead of evidence, and how external innovators can build capabilities that are differentiated, scalable and relevant to real R&D needs.
The discussion will focus especially on intelligent and agentic AI: systems that move beyond generating outputs toward supporting scientific reasoning, orchestrating workflows, planning experiments, analyzing results and helping teams move faster from data to insight. Rather than treating AI as a generic productivity layer, the program will ask where AI can become part of the operating model for drug discovery and development, from target identification and validation to biomarker discovery, endpoint development, therapeutic design, clinical development and regulatory workflows.
Basel provides a strong setting for this conversation. The activation is planned alongside BioTechX Europe, bringing together a large community of data, AI, genomics and pharma stakeholders already present in the city.
If you are working on AI, data science or digital health capabilities with potential to transform drug discovery and development, we invite you to join the conversation and connect with Johnson & Johnson leaders and the Basel life sciences innovation community.
Â
- Paul Ashley | Director External Innovation for Data, Data Science & AI, Johnson & Johnson Innovative Medicine R&D
- Moderator - Michael Hübner | Director, Search & Evaluation EMEA
Country Lead External Scientific Innovation - Switzerland, Austria, Italy, Johnson & Johnson
- Further panelists to be announced shortly
Â
This program is from Johnson & Johnson and represents a selection of activities from across our Innovation Centers, JLABS and JJDC. The information in this program is for informational purposes only. The information is either proprietary or licensed to Johnson & Johnson and its affiliates or is provided by or proprietary to third parties. In case of third-party information, please note that only those third parties that provided or own this information are responsible for it. By providing this information, Johnson & Johnson do not endorse these third parties or any of the information provided in this program. This content is not intended to influence the use, sale, recommendation, or promotion of any products or services of Johnson & Johnson. Johnson & Johnson is not responsible or liable for any actions you do or do not take in relation to this information and are not responsible for any use of this information by you. By providing the information in this program, Johnson & Johnson does not make any representations, warranties, or assurances, express or implied, as to the content or the information presented in this program and is not responsible for any use by or alterations of this information by you. Johnson & Johnson hereby expressly disclaims any and all guarantees, representations, warranties, or assurances and assumes no responsibility or liability, direct or indirect in relation to the information in this program.